Breast Cancer

Patients with HER2-positive early breast cancer derived similar outcomes whether they received subcutaneous or intravenous pertuzumab and trastuzumab plus chemo.

Treatment with fuzuloparib, either with or without apatinib, provided superior progression-free survival benefit compared with chemotherapy in HER2– metastatic breast cancer with germline BRCA1/2 mutations.

Adding inavolisib to palbociclib and fulvestrant improved results for HER2-negative, hormone receptor–positive, PIK3CA-mutated advanced or metastatic breast cancer.

Patients with MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer had improved recurrence-free survival when treated with anthracycline/taxane/cyclophosphamide.

Patients with HR-positive, HER2-low, and -ultralow metastatic breast cancer treated with trastuzumab deruxtecan obtained a PFS benefit vs chemotherapy.

Most survivors of stage I-III breast cancer who attempted pregnancy succeeded, though there were certain factors that seemed to increase the chance of conception.

Adding capivasertib to fulvestrant was shown to improve the time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Compared with physician’s choice of treatment, trastuzumab deruxtecan exhibited superior long-term survival and response rates in patients with HER2-positive breast cancer.

Compared with chemotherapy alone, atezolizumab plus chemotherapy did not improve overall survival in select patients with early relapsing triple-negative breast cancer.

The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved distant recurrence-free survival.

The final breast cancer screening recommendation from the United States Preventive Services Task Force advises that women aged 40 should begin biennial screening.

Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

From journaling to delegating everyday tasks, nurses can teach patients how to cope with treatment-related fatigue.

Trastuzumab-strf was approved for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

A pilot study proved that a nurse-coordinated approach shows promise in treating more than just 1 symptom among patients with cancer.

Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.

Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.

The optical imaging agent Lumisight and the Lumicell Direct Visualization System received approval from the FDA for fluorescence imaging in breast cancer.

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

Patients with early-stage breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor provided a greater invasive disease-free survival benefit compared with nonsteroidal aromatase inhibitor therapy alone.